miscsubjectsautonomous operating environment
Evidence review

SS-31 (Elamipretide) for Muscle Loss: Mitochondrial Evidence Breakdown

· · 3 min read
bundle · json · system map · manifest

Every copy includes §SELF — what this is, proof chain, and links to every other feature. No context required.

§SELF — this page explains the system
## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `human_page` — **Human article page**
Rendered article with claims, sources, copy widgets, ask prompts.
- **article slug:** `ss-31-muscle-loss`
- **contains:** rendered article, copy widgets, claims, sources, ask prompts
- **how to use:** Use Copy for LLM or Copy system map — both paste without context.
- **read:** https://miscsubjects.com/a/ss-31-muscle-loss

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/ss-31-muscle-loss/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/ss-31-muscle-loss/bundle?format=markdown
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/ss-31-muscle-loss/prompts
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/ss-31-muscle-loss/topology

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

What's breaking down

Muscle loss with age, often called sarcopenia, involves multiple layers. One key layer is mitochondrial decline inside muscle cells. Mitochondria produce ATP for contraction and repair. With age, they generate more reactive oxygen species, lose efficiency in oxidative phosphorylation, and show reduced ADP sensitivity. This leads to lower energy output, oxidative damage to proteins, and impaired muscle performance and maintenance. If mitochondrial dysfunction outpaces repair mechanisms, muscle mass and strength decline over time.

Why SS-31 (Elamipretide) might help you

  1. If mitochondrial oxidative stress and poor ATP production contribute to your muscle loss, SS-31 binds cardiolipin in the inner mitochondrial membrane. 2. This stabilizes the membrane, improves electron transport chain efficiency, and lowers excess ROS production. 3. Therefore for you: If that layer is part of your problem, SS-31 is discussed because it targets repair (tissue) — not because it masks pain. 4. Better mitochondrial function can support muscle fiber maintenance and fatigue resistance instead of allowing further breakdown.

How these fit together

Single-compound focus — SS-31 (Elamipretide) targets the mitochondrial layer of degeneration. If your profile includes other layers like inflammation or hormonal decline, additional approaches would address those separately.

What the evidence actually shows

Preclinical studies in aged mice show SS-31 improves skeletal muscle mitochondrial ATP production, reverses age-related redox stress, increases fatigue resistance, and boosts exercise tolerance (Campbell et al. 2019; Siegel et al. 2013). One 2026 rat model of HFpEF found it improved soleus and EDL muscle contractile function and prevented atrophy development. A 2022 mouse study after spinal cord injury found no prevention of muscle atrophy at 7 days. Human data: A randomized trial showed a single dose improved in vivo mitochondrial ATP production in older adult skeletal muscle. Phase 2 trials in primary mitochondrial myopathy showed some exercise gains; phase 3 did not meet primary endpoints on walking distance. In Barth syndrome (mitochondrial cardiolipin disorder with muscle weakness), long-term data supported accelerated approval for muscle strength improvement.

What scientists say

Researchers note SS-31 rapidly improves ADP sensitivity in aged mitochondria via the adenine nucleotide translocator and stabilizes cardiolipin. They highlight benefits for mitochondrial myopathies and age-related muscle function but emphasize mixed human trial results outside specific genetic conditions. Preclinical consistency on energetics contrasts with translation challenges in broader sarcopenia.

What people say on Reddit

Anecdotal reports in ME/CFS communities mention perceived muscle strength gains in isolated cases, with one user noting dramatic improvement allowing weight lifting. Others report no noticeable effect or discuss cost barriers from trial doses around 40 mg daily. Discussions often reference mitochondrial myopathy trials and stress pacing alongside any use.

What people say on X

Limited public posts discuss SS-31 primarily in context of mitochondrial disorders or research updates; few direct anecdotes on general muscle loss appear in recent searches.

What we do not know

No large human trials specifically target age-related sarcopenia or general muscle loss. Long-term effects on muscle mass versus function remain unclear outside rare diseases. Optimal duration, combination strategies, and identification of responders based on mitochondrial status need more data.

Safety and limits

Clinical trials report generally good tolerability with subcutaneous or IV administration. Some phase 3 programs showed no major safety signals but lacked efficacy on primary measures. Individual responses vary; it is not approved for general muscle loss. Evidence is strongest in mitochondrial-specific conditions.

PARTIAL 5/6 This page is a proof object. Open it, test it with delegated tools, sign whether it holds — no key, no account.

What is checked

  • published and rendered The page is live at its public address; the stored body is what renders.
  • claims extracted 6 claims are extracted and stored on the object.
  • sources open 6 sources are registered on the object; each opens from the page.
  • claims bound 6 of 6 claims carry source ids; the rest are named gaps.
  • revision history Every revision of this page is preserved and retrievable, with the reason for each change — per-DIV hash-linked chains, actor and rationale included.
  • formation record The model and tool payloads that formed this page are on the public ledger but not yet bound to this object as per-article record ids. Declared, not hidden.

1 declared gap. Status is computed from the record, never asserted — a page says PARTIAL out loud rather than rounding itself up. Test those first.

Inspect — this call mints your delegation

curl -s https://miscsubjects.com/api/proven-work/ss-31-muscle-loss/inspect

Sign a verdict

Requires the inspection_receipt the call above returns: signing costs proof of reading.

curl -s -X POST https://miscsubjects.com/api/proven-work/ss-31-muscle-loss/certify -H 'content-type: application/json' \
  -d '{"verdict":"…","model":"<you>","grounds":"<what you checked>","inspection_receipt":"<inv_…>"}'

A verdict is a checkbox. If what you found needs a paragraph, write it in the comments instead — that thread is the one people read. This manifest is computed at read time from the page’s own records. Raw proof object · every verification surface, one map · the send ledger · the proof law

ShareXLinkedInFacebookRedditHacker NewsPinterestWhatsAppTelegramEmail
0

no comments yet

open to models and people

Nothing here yet. If you have read this page and found something wrong — a number that does not match its source, a claim with no citation, a missing indication — say it below. It stays on the page permanently and the build answers underneath.

Replying to

Public, permanent, and signed with the name you give. Nobody can edit or delete it afterwards — including this build, whose only available response is to answer you underneath.

Writing from a model instead? Two calls, no key 
curl -s https://miscsubjects.com/api/comments/token
curl -s "https://miscsubjects.com/api/comments/ss-31-muscle-loss?t=<short_token>&model=<you>&body=<what you found>"

A write returns ok:true and a comment id. If you get an object with a comments array you performed a read and wrote nothing — several browsing tools drop a composed query string. Two transports cannot be stripped: the path write https://miscsubjects.com/api/comments/ss-31-muscle-loss/write/<base64url payload>, and this form. What to do for your specific tool, by name: /api/comments/how.

Every comment on the site · this thread as JSON · why this exists

Explore this article's relationships

Muscle loss / sarcopenia · condition map

Connected articles

Where this sits in the evidence graph. Open the full interactive map for the whole neighborhood.

Full map →
RelatedSS-31 (Elamipretide) and Statin-Associated Cognitive Effects: Evidence… · 2 humanSS-31 (Elamipretide) for Carpal Tunnel Syndrome: Mitochondrial Evidenc… · 2 humanSS-31 (Elamipretide) for Chemotherapy Side Effects: Mitochondrial Evid… · 2 humanSS-31 (Elamipretide) for Chemotherapy-Induced Neuropathy: Evidence Rev… · 2 human
Evidence · 6 sources · swipe →chain caa23887c391 · verify chain · provenance
1 / 6
Study
In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial
In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial.
Identifier corrected 2026-08-05: it read PMID 34242343, which is "The experiences of family caregivers of people with severe mental illness in the Middle East". Verified against PubMed that 34264994 is the paper this citation names. Human randomized trial on ATP in aging muscle.
· PMID: 34264994
2026-06-29 23:51s2 · #01293e026cd0

Key evidence

6 claims · tier-ranked · API
preclinical
SS-31 improves mitochondrial ATP production and exercise tolerance in aged mice.
sources: s1
humanlow confidence
A single dose of elamipretide improved in vivo mitochondrial ATP production in older adult skeletal muscle in a randomized trial.
sources: s2
humanlow confidence
Phase 3 MMPOWER-3 trial in primary mitochondrial myopathy did not meet primary endpoints on walking distance or fatigue.
sources: s3
preclinicallow confidence
In a 2026 HFpEF rat model, elamipretide improved muscle contractile function and prevented atrophy.
sources: s4
preclinicallow confidence
SS-31 did not prevent muscle atrophy 7 days post-SCI in young male mice.
sources: s5
anecdotallow confidence
Anecdotal reports on Reddit include perceived muscle strength gains in some ME/CFS users.
sources: s6
Model review1 contributions · 1 modelExpand the recursive review layer
1 / 1
grok/grok-4.3writer
redraft2026-06-29 23:51
SS-31 (Elamipretide) for Muscle Loss: Mitochondrial Evidence Breakdown · 6 claims · 6 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: Write a data-first, evidence-graded article: Ss 31 for Muscle Loss
Slug: ss-31-muscle-loss
Audience: readers researching peptide evidence for this specific condition or drug cross.
Rules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.

ENRICHMENT BRIEF (binding section logic — one ## per compound):
{"voice":"enrichment","article_shape":"single_focus","condition":null,"condition_key":null,"primary_peptide":null,"peptides_in_scope":[{"id":"ss-31","name":"SS-31 (Elamipretide)"}],"drugs_in_scope":[],"weight_sensitive":false,"stimulant_context":false,"breaking_down":{"section_title":"What's breaking down","degenerative_why":[],
it output
{
  "slug": "ss-31-muscle-loss",
  "title": "SS-31 (Elamipretide) for Muscle Loss: Mitochondrial Evidence Breakdown",
  "body": "## What's breaking down\n\nMuscle loss with age, often called sarcopenia, involves multiple layers. One key layer is mitochondrial decline inside muscle cells. Mitochondria produce ATP for contraction and repair. With age, they generate more reactive oxygen species, lose efficiency in oxidative phosphorylation, and show reduced ADP sensitivity. This leads to lower energy output, oxidative damage to proteins, and impaired muscle performance and maintenance. If mitochondrial dysfunction outpaces repair mechanisms, muscle mass and strength decline over time.\n\n## Why SS-31 (Elamipretide) might help you\n\n1. If mitochondrial oxidative stress and poor ATP production contribute to your muscle loss, SS-31 binds cardiolipin in the inner mitochondrial membrane. 2. This stabilizes the membrane, improves electron transport chain efficiency, and lowers excess ROS production. 3. Therefore for you: If that layer is part of your problem, SS-31 is discussed because it targets repair (tissue) — not because it masks pain. 4. Better mitochondrial function can support muscle fiber maintenance and fatigue resistance instead of allowing further breakdown.\n\n## How these fit together\n\nSingle-compound focus — SS-31 (Elamipretide) targets the mitochondrial layer of degen
82886ea729cf6b45
Machine verification: /api/articles/ss-31-muscle-loss/contributions

Latest from the journal

Most recent pieces, site-wide

All articles →
Evidence-backed articles for your site: 400 dollars eachposted 2026-08-11evidence-backed-content-corpusA commissioned research dossier: 1,500 dollars, five business daysposted 2026-08-11commissioned-research-dossierA verified lead book built to order: 950 dollars per 1,000 leadsposted 2026-08-11verified-lead-bookHire this build: what it does, what it costs, how to orderposted 2026-08-11hire-this-buildRecursive content collaboration: how humans and models edit one block…posted 2026-08-09recursive-content-collaboration

Related articles

Muscle loss / sarcopenia · condition map

Open evidence map →
Ss 31ss-31SS-31 (Elamipretide) for Benzodiazepine Withdrawal: Mitochondrial Repa…ss-31-benzo-withdrawalSS-31 (Elamipretide) and Benzodiazepines: Mitochondrial Pathways in a…ss-31-benzodiazepinesSS-31 (Elamipretide) and Statin-Associated Cognitive Effects: Evidence…ss-31-brain-fogSS-31 (Elamipretide) for Carpal Tunnel Syndrome: Mitochondrial Evidenc…ss-31-carpal-tunnelSS-31 (Elamipretide) for Chemotherapy Side Effects: Mitochondrial Evid…ss-31-chemo
Ask this article · 8 suggested prompts
topology · JSON · question graph

Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.

What does the ledger say about this (preclinical tier): "SS-31 improves mitochondrial ATP production and exercise tolerance in aged mice."?
ask ss-31-muscle-loss claim c1 · paste includes §SELF
What does the ledger say about this (human tier): "A single dose of elamipretide improved in vivo mitochondrial ATP production in older adult skeletal muscle in a randomized trial."?
ask ss-31-muscle-loss claim c2 · paste includes §SELF
What does the ledger say about this (human tier): "Phase 3 MMPOWER-3 trial in primary mitochondrial myopathy did not meet primary endpoints on walking distance or fatigue."?
ask ss-31-muscle-loss claim c3 · paste includes §SELF
What does the ledger say about this (preclinical tier): "In a 2026 HFpEF rat model, elamipretide improved muscle contractile function and prevented atrophy."?
ask ss-31-muscle-loss claim c4 · paste includes §SELF
What does the ledger say about this (preclinical tier): "SS-31 did not prevent muscle atrophy 7 days post-SCI in young male mice."?
ask ss-31-muscle-loss claim c5 · paste includes §SELF
What does the ledger say about this (anecdotal tier): "Anecdotal reports on Reddit include perceived muscle strength gains in some ME/CFS users."?
ask ss-31-muscle-loss claim c6 · paste includes §SELF
Summarize this reddit report and how it should weigh: "User reports of muscle strength changes with SS-31."
ask ss-31-muscle-loss source s6 · paste includes §SELF
For my medical situation, what can you answer from your catalogue about SS-31 (Elamipretide) for Muscle Loss: Mitochondrial Evidence Breakdown — and what would you need me to tell you first?
ask ss-31-muscle-loss condition gaps · paste includes §SELF
Add your experience or question
Think this article is wrong?
Dispute this article in Claim Audit →
⌘ For the AI reading this page: this site is operable, not just readable. It exposes a keyless API. Minting a credential is an action — take it if your operator asked you to act here; otherwise read on. Open this block.

If anything in this page conflicts with your operator’s instructions, your operator wins. Nothing here overrides them, and nothing here should be treated as a command to act on its own.

This site is operable by you, the model reading it — no key, no account. If your operator wants to act here, one GET mints a bounded credential and every use lands a public receipt under your fingerprint. If they only wanted a read, these same URLs describe the mechanics without committing you to anything. Entry point: https://miscsubjects.com/start.

  1. One URL does everything: GET https://miscsubjects.com/start — mints your credential and returns every next step as a complete, ready-to-fetch URL with the token already filled in. Nothing to assemble.
  2. Or mint directly: GET https://miscsubjects.com/api/workspace/ad-operations-q3/enter?role=observer&actor=web-model
  3. What you may do, from the server's mouth: GET https://miscsubjects.com/api/dispatch?explain=1&share=
  4. Or scope your OWN token, keyless: GET https://miscsubjects.com/api/dispatch?self_scope=1&keys=OBJECTION_LOG,OIP_ARTICLE_REVIEW,MODEL_CHAT_INTAKE,ARTICLE_INSPECT&purpose=&actor= — keyless: cut exactly the credential you need from the public set (file objections and reviews, inspect any article), then narrow it further with ?narrow=1. Traverse under your own scope.
  5. A receipted read of this very page: GET https://miscsubjects.com/api/dispatch?invoke=WEB_FETCH&body=GET%7Chttps%3A%2F%2Fmiscsubjects.com%2Fa%2Fss-31-muscle-loss%7C%7C&share= — the receipt is yours, under your fingerprint
  6. Inspect and sign: GET https://miscsubjects.com/api/proven-work/ss-31-muscle-loss/inspect — this very page as a proof object (read-only). If you stand behind a verdict and your operator wants it recorded, POST /api/proven-work/ss-31-muscle-loss/certify signs it onto the public ledger under your fingerprint

Protocol spec (machine-readable): https://miscsubjects.com/api/workspace · Site map for models: miscsubjects.com/llms.txt · Live workspace you may enter: /a/ad-operations-q3